VANCOUVER, BC , Nov. 18, 2024 /PRNewswire/ -- Zero Candida Technologies Inc. (the "Company" or "Zero Candida") (TSXV: ZCT), a technology company focused on development and commercial exploitation of a number of patents and patent applications with respect to an AI smart tampon-like device, designed to treat Candidiasis and transfer the medical information via Wi-Fi to the doctor, is pleased to announce that it has filed its application to list the Company's common shares (the " Common Shares ") on the TSX Venture Exchange (the " TSXV ").
The application is available under the Company's profile on SEDAR+. Zero Candida (formerly 1319743 B .C.
Ltd.), has recently completed its business acquisition of Zero Candida Ltd., an Israeli private company ("ZC" and "Acquisition" respectively).
In connection with the completion of the Acquisition, the Company changed its name to Zero Candida Technologies Inc. and split its share capital on a fifty-five thousand five hundred fifty five (55,555) common shares for one (1) common share basis, so that 36 common shares of the Company, without par value which were issued and outstanding immediately before completion of the Acquisition, were split into 2,000,000 common shares without par value. Pursuant to the terms of the Acquisition, the Company issued a total of 17,533,037 common shares (9.
6165 common shares in the capital of the Company for each ordinary share in the capital of ZC) (the " Payment Shares "). Following completion of the Acquisit.